Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855305 · ClinicalTrials.gov registry record · Phase 2
Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
A Phase 2 study, sponsored by Bastiaan Driehuys.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT04855305 is a Phase 2 study that has completed, run by Bastiaan Driehuys. The registered enrollment target is 46 participants.
The verdict
NCT04855305, a Phase 2 study, has completed, sponsored by Bastiaan Driehuys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
Interventions
- DRUG Hyperpolarized 129Xe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04855305
The ClinicalTrials.gov registry entry for NCT04855305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperpolarized 129Xe is the first listed.
NCT04855305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04855305 about?
NCT04855305 is a clinical study titled "Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease". The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
What is the current status of trial NCT04855305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2021-11-12. Estimated completion is 2025-06-11.
What interventions are being tested in trial NCT04855305?
The interventions under investigation include: Hyperpolarized 129Xe (DRUG).
Who is sponsoring clinical trial NCT04855305?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.